Lopinave/Litonawe (LPV/r) reduced mortality in studies of SARS and MERS: uncertain if it is effective for patients with COVID-19
MetadatosMostrar el registro completo del ítem
What is this? Like COVID-19, severe acute respiratory syndrome (SARS) and the Middle East respiratory syndrome (MERS) are acute respiratory diseases caused by a coronavirus. Antiviral therapy with Lopinave/Litonawe (LPV/r) was used to treat patients with these earlier coronaviruses and might be considered as a treatment for COVID-19. In this rapid systematic review, the authors searched Chinese and English literature databases for research of any design that compared LPV/r versus either placebo or standard care for patients with SARS or MERS, published between January 2003 and 24 January 2020. They identified 2 cohort studies (both for SARS patients), 1 case report (for MERS patients) and 1 clinical guideline (for MERS patients).